After Today’s Big Increase, Is DBV Technologies S.A. (DBVT)’s Near-Term Analysis Positive?

DBV Technologies S.A. (NASDAQ:DBVT) Logo

The stock of DBV Technologies S.A. (NASDAQ:DBVT) is a huge mover today! The stock increased 7.27% or $0.7 during the last trading session, reaching $10.29. About 564,172 shares traded or 173.12% up from the average. DBV Technologies S.A. (NASDAQ:DBVT) has declined 46.50% since September 13, 2018 and is downtrending. It has underperformed by 46.50% the S&P500.
The move comes after 6 months positive chart setup for the $749.81M company. It was reported on Sep, 13 by Barchart.com. We have $10.91 PT which if reached, will make NASDAQ:DBVT worth $44.99 million more.

More notable recent DBV Technologies S.A. (NASDAQ:DBVT) news were published by: Benzinga.com which released: “Biotech Stock On The Radar: Aimmune Awaits Adcom Test – Benzinga” on September 10, 2019, also Seekingalpha.com with their article: “DBV Tech down 62% premarket on withdrawal of U.S. marketing application for Viaskin Peanut – Seeking Alpha” published on December 20, 2018, Benzinga.com published: “25 Healthcare Stocks Moving In Today’s Pre-Market Session – Benzinga” on August 08, 2019. More interesting news about DBV Technologies S.A. (NASDAQ:DBVT) were released by: Bizjournals.com and their article: “Peninsula biotech lines up chance to crack the peanut allergy nut – San Francisco Business Times” published on March 25, 2019 as well as Nasdaq.com‘s news article titled: “Here’s Why Aimmune Therapeutics Fell 7% Today – Nasdaq” with publication date: July 11, 2019.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. The company has market cap of $749.81 million. The Company’s lead product candidate is Viaskin Peanut, an immunotherapy product, which is in Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. It currently has negative earnings. The firm is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cowÂ’s milk protein allergy and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of henÂ’s egg allergy; and booster vaccine for Bordatella pertussis.

DBV Technologies S.A. (NASDAQ:DBVT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.